Insys Therapeutics Inc (INSY) 62.42 $INSY Insys

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 11:09 AM

Insys Therapeutics Inc (INSY) 62.42 $INSY

Insys Therapeutics to Report First Quarter 2015 Results
Marketwired - Thu Apr 23, 3:30PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the first quarter 2015 on Thursday, May 7, 2015, before the U.S. financial markets open.
INSY: 62.42 (-1.90)

Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
Marketwired - Thu Apr 23, 6:00AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company"

today announced that it has commenced dosing of pediatric epilepsy patients in a Phase 1/2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant seizures.
INSY: 62.42 (-1.90)

GTSO Encounters Unprecedented Industry Demand at Denver's Blockbuster Cannabis Cup
Business Wire - Thu Apr 23, 4:00AM CDT
Green Technology Solutions, Inc. (OTCBB: GTSO) representatives returned from Denver this week with a wealth of new business leads and marketing ideas after extensive networking at the country's premiere cannabis industry event, Cannabis Cup Denver.
INSY: 62.42 (-1.90)

Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part V
Anthony Cataldo - at Seeking Alpha - Sat Apr 18, 6:09AM CDT

INSY: 62.42 (-1.90)

NTRR Reviews Latest Cannabis Innovations at Denver's Big Industry Show
Business Wire - Thu Apr 16, 4:00AM CDT
Neutra Corp. (OTCBB: NTRR) CEO Chris Brown traveled to Colorado this week to meet with retailers and review the latest products and innovations in the cannabis industry at the annual Big Industry Show in Denver.
INSY: 62.42 (-1.90)

5 Biotechnology Bargains Revisited
Joseph P. Porter - at Seeking Alpha - Wed Apr 15, 8:22AM CDT

INSY: 62.42 (-1.90), BSTC: 37.75 (-0.24), NLNK: 52.10 (-0.90), ENTA: 37.14 (+0.56), ANIK: 38.35 (-0.32)

Short Interest In Insys Therapeutics Expands By 10.7%
MarketNewsVideo.com - Tue Apr 14, 3:28PM CDT
The most recent short interest data has been released by the NASDAQ for the 03/31/2015 settlement date, which shows a 610,489 share increase in total short interest for Insys Therapeutics Inc , to 6,331,104, an increase of 10.67% since 03/13/2015. ...
INSY: 62.42 (-1.90)

NTRR: Preliminary Results of Horticultural Product Testing Exceed Expectations
Business Wire - Tue Apr 14, 8:42AM CDT
The preliminary results of lab testing on the suite of horticultural products being marketed by Neutra Corp. (OTCBB: NTRR) and its joint venture partner, Surface to Air Solutions, Inc. (S2O2), have so far exceeded all expectations, the company announced today.
INSY: 62.42 (-1.90)

GTSO Plans Edibles Tour of California and Colorado to Refine Market Strategy
Business Wire - Tue Apr 14, 8:39AM CDT
As Green Technology Solutions, Inc. (OTCBB: GTSO) works to develop new products for the booming U.S. cannabis edibles market, representatives of the company will travel to California and Colorado--two the of the country's biggest marketplaces for edibles--to meet with retailers and refine its strategy to better serve the demands of dispensaries nationwide.
INSY: 62.42 (-1.90)

NTRR and S2O2 Deliver New Weapons Against Mold in Colorado's Billion-Dollar Cannabis Industry
Business Wire - Thu Apr 09, 4:00AM CDT
As the state government agencies work to eliminate the threat of mold contamination in Colorado's booming cannabis industry, Neutra Corp. (OTCBB:NTRR) and its joint venture partner, Surface to Air Solutions, Inc. (S2O2), stand ready with a possible solution to the problem.
INSY: 62.42 (-1.90)

NTRR Joint Venture Offers New Antimicrobial Solutions to Embattled Colorado Cannabis Growers
Business Wire - Tue Apr 07, 6:21AM CDT
As testing continues in Colorado on horticultural products marketed by Neutra Corp. (OTCBB:NTRR) and its joint venture partner, Surface to Air Solutions (S2O2), the companies are already receiving a great deal of interest from cannabis growers in the state. In response, each Friday in April, S2O2 will conduct educational information sessions on its suite of antimicrobial alternatives to pesticides, hosted by respected cultivation organization Denver Consulting Group.
INSY: 62.42 (-1.90)

Shortage of Qualified Cannabis Testing Labs Spells Opportunity for GTSO
Business Wire - Tue Apr 07, 6:05AM CDT
A distinct shortage of Colorado labs equipped to test adult-use cannabis for contaminants such as bacteria and mold could produce major opportunities for Green Technology Solutions, Inc. (OTCBB:GTSO).
INSY: 62.42 (-1.90)

The Best Stocks to Invest in Marijuana
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 04, 1:08PM CDT
The 2014 elections created a lot of excitement among marijuana supporters, as voters in Oregon, Alaska, and the District of Columbia expanded the number of jurisdictions allowing recreational marijuana use. This has policy makers thinking 2016...
INSY: 62.42 (-1.90), GWPH: 121.00 (+0.23)

Don't Play With Propane - Cramer's Lightning Round (4/1/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Apr 02, 6:02AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, April 1. Bullish Calls: Insys Therapeutics (NASDAQ: INSY ): "Good company. Makes money, but be careful because Johnson & Johnson (NYSE: JNJ )...
MNK: 122.01 (-2.84), KMI: 44.34 (-0.23), KSS: 74.59 (-2.19), MCK: 229.20 (+0.09), UNH: 118.69 (+0.43), ALK: 68.30 (+1.96), AGEN: 7.12 (+0.75), URBN: 41.90 (-0.49), DDS: 136.53 (-1.32), SBUX: 51.84 (+2.41), JNJ: 101.08 (+0.62), HCA: 77.74 (+0.30), INSY: 62.42 (-1.90), DNKN: 54.03 (+2.52), AMAT: 21.80 (-0.37), FGP: 24.53 (+0.22), BIG: 47.57 (-0.16), KPTI: 31.49 (-1.13)

'Mad Money' Lightning Round: Kinder Morgan, HCA Are Winners
at The Street - Thu Apr 02, 5:00AM CDT
Cramer says to be careful on Insys Therapeutics, prefers Starbucks over Dunkin Brands and would buy Alaska Air.
KMI: 44.34 (-0.23), KSS: 74.59 (-2.19), MCK: 229.20 (+0.09), UNH: 118.69 (+0.43), ALK: 68.30 (+1.96), URBN: 41.90 (-0.49), SBUX: 51.84 (+2.41), AGEN: 7.12 (+0.75), DDS: 136.53 (-1.32), HCA: 77.74 (+0.30), DNKN: 54.03 (+2.52), INSY: 62.42 (-1.90), AMAT: 21.80 (-0.37), FGP: 24.53 (+0.22), BIG: 47.57 (-0.16), KPTI: 31.49 (-1.13)

NTRR Scouts Opportunities in New Cannabis States to Offer Cleaner Growing Solutions
Business Wire - Thu Apr 02, 4:00AM CDT
As cannabis reform continues to sweep across North America from coast to coast, Neutra Corp. (OTCBB: NTRR) will pursue new opportunities to improve cultivation methods in territories where the plant is legal and regulated with a ground-breaking suite of horticultural products.
INSY: 62.42 (-1.90)

GTSO Engineers New Solutions to Colorado Cannabis Industry's Pesticides Problem
Business Wire - Thu Apr 02, 4:00AM CDT
As Green Technology Solutions, Inc. (OTCBB:GTSO) works to establish its new cannabis testing laboratory, state regulators in Colorado are stepping in to ensure that all cannabis products under their jurisdiction are free from potentially harmful pesticides and other contaminants.
INSY: 62.42 (-1.90)

Jim Cramer's 'Mad Money' Recap: Get Ready for a Rough Ride
at The Street - Wed Apr 01, 7:22PM CDT
Supply is the true enemy of the bull and there's a lot of new supply hitting the markets, Cramer says.
CXO: 125.84 (-0.64), KMI: 44.34 (-0.23), TSLA: 218.43 (-0.17), KSS: 74.59 (-2.19), GE: 26.80 (-0.05), EMES: 44.65 (-5.95), FRPT: 22.86 (+0.15), UTX: 116.16 (-1.10), UNH: 118.69 (+0.43), FCX: 20.82 (+0.75), BPT: 69.07 (-0.53), SDRL: 11.39 (-0.26), SLB: 91.61 (-1.44), SBUX: 51.84 (+2.41), DNKN: 54.03 (+2.52), INSY: 62.42 (-1.90), LNCO: 12.13 (-0.24), AMAT: 21.80 (-0.37), CRZO: 53.43 (-0.60), FGP: 24.53 (+0.22), AAPL: 130.28 (+0.61), SIRI: 3.96 (+0.03), ABT: 48.32 (-0.14), MCK: 229.20 (+0.09), BMY: 65.80 (-0.20), ALK: 68.30 (+1.96), ARP: 9.20 (+0.04), URBN: 41.90 (-0.49), DDS: 136.53 (-1.32), AGEN: 7.12 (+0.75), PM: 82.75 (-0.80), HCA: 77.74 (+0.30), RDS.A: 62.76 (-0.20), TXMD: 7.12 (-0.12), BIG: 47.57 (-0.16), GDDY: 25.63 (+0.58), KPTI: 31.49 (-1.13)

Insys Therapeutics Inc. Poised For Strong Growth In Earnings Ahead
Christopher Stoehr - at Seeking Alpha - Wed Apr 01, 7:43AM CDT

INSY: 62.42 (-1.90), GWPH: 121.00 (+0.23), PFNX: 15.80 (-0.20)

Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phwnn8/lennoxgastaut) has announced the addition of the "Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Lennox-Gastaut Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - H. Lundbeck A/S - GW Pharmaceuticals plc - INSYS Therapeutics, Inc. - SymPhar Sp. z.o.o. - ProductLife Group SA - Mylan Inc. - Johnson & Johnson - GlaxoSmithKline plc - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/ph...noxgastaut
JNJ: 101.08 (+0.62), INSY: 62.42 (-1.90), GSK: 46.59 (+0.28)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ex-Guard Pushes Cost-Saving Grille Guards as Deer Season Hits

Deer Season's Bumper Problem If you're driving a hefty pickup or van in the thick of deer season, forget looking at pretty autumn leaves. Instead, brace for the telltale thud—and the ensuing financial headache—that comes with a deer collision. Anyone who's tangled with such a mishap knows it's not just about the dent in your fender; it's about your wallet getting...

Meitu Sees Soaring Subscriber Growth Amid AI Focus

Subscriber Growth Hits a Record High Well, here's a headline to chew on—Meitu, Inc. is boasting a whopping 19.83 million paying subscribers, setting a new milestone. That's 1.39 million new users this quarter alone, the most significant uptick they've seen in four cycles. Not that I'm surprised; when you've got a product mix like theirs that's riding high on the wave of...

Nicely Network: A Game-Changer for B2B SaaS Marketing

Navigating the Reddit Marketing Labyrinth Life ain't a walk in the park for marketers these days, especially in the tech and SaaS arenas. Some folks seem to have cracked the code—or at least one part of it. Enter Nicely Network, which has just snagged the crown as the Best Reddit Marketing Agency for B2B SaaS & Software Companies, thanks to its knack for connecting...

Tabañero Spices Up Holidays with $10 Gift Sets

Hot Sauce, Spicy Gifting, and Bold Barbecue When holiday cheer mixes with a dash of heat, you end up with something as electrifying as Tabañero's latest offerings. This Florida-based player is nudging its way into the gift-giving scene with a lineup that's as spicy as it is thoughtful. Frankly, if you're scrambling for stocking stuffers or a memorable Secret Santa...

Honeywell Aerospace Posts Solid Q3, Raises Guidance

Honeywell Aerospace Surprises with Strong Third Quarter In a world where numbers are often as slippery as a greased pig, Honeywell Aerospace (NASDAQ:HONA) has managed to pin down a surprisingly robust third quarter. Let’s break it down: they’ve claimed sales of a cool $4.6 billion, reflecting a 2% bump both in reported and organic revenue from the previous year, and...

ZYNLONTA's Japanese Push: ADC Therapeutics Gains Traction

ADC Therapeutics Eyes Japan with ZYNLONTA Bet These days, everyone seems to have their eyes on the Far East, and ADC Therapeutics is no exception. They're making a strategic leap by letting their budding blockbuster ZYNLONTA make waves in Japan. With the fresh file submitted for approval, it looks like they're hoping to capture market ground that could pay off big time...

Factory-Built Homes Take Center Stage in New Doc Short

Housing is one of those things we all think we understand until we start peeling back the layers of its history, especially when factory-built homes are involved. Here's a new angle: Clayton has just released the teaser for their documentary short, "Built: A Story of Factory-Built Housing in America," and it's turning the lights on a sector that's often left in the...

Virax Biolabs Expands China Reach With Key Partnerships

Virax Biolabs' Strategic Play in China Does Virax Biolabs have a trick up its sleeve, or is it just rolling the dice in the vast Chinese market? With three new distributor agreements, it sure seems like it's trying to tip the scales in its favor. The London-based company announced new distribution agreements for its ImmuneSelect research-use immune profiling products....

Withings Sleep Care Service Tackles Post-Time Change Fatigue

Counting Sheep: More Minutes or Just More Trouble? As Americans prepare for the clocks to fall back, many dream of an extra hour of sleep. But according to Withings, the reality is far less restful. Despite the clock change promising more shut-eye, folks average just 11 minutes extra sleep, only to watch that dissipate in the days following. Somehow, we lose more than we...

Corgi Revamps Malpractice Insurance for Healthcare Sector

Streamlining Insurance for Healthcare Professionals Here's one for the books in the insurance world: Corgi Insurance is stepping up to spare healthcare practices from the headache of getting medical malpractice coverage. This is more than just insurance talk; it's about time someone carved out a path through the labyrinth of medical malpractice policies. Healthcare folks...